ArticleJournal of neurology2011
Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study.
Article in Journal of neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- The effectiveness of physiotherapy for patients with isolated cervical dystonia: an updated systematic review and meta-analysis.BMC neurology · 2024Pooled it
- Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value.Journal of neurology · 2012Pooled it
- The effect of botulinum neurotoxin injection on non-motor symptoms of cervical dystonia: A prospective cohort.Acta neurologica Belgica · 2026Article
- Balance, Gait Kinematics, and Fear of Falling After a Four-Month Targeted Training Program in a Patient with Cervical Dystonia: A Case Report.International journal of environmental research and public health · 2025Article
- Optimal botulinum toxin therapy of dystonia in Germany: what would it cost?Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Pioneering pain management with botulinum toxin type A: From anti-inflammation to regenerative therapies.Heliyon · 2025Review
- Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom.ClinicoEconomics and outcomes research : CEOR · 2017Article
- AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis.ClinicoEconomics and outcomes research : CEOR · 2015Article
- A retrospective study to assess resource utilization in patients with cervical dystonia in the United Kingdom.Neuropsychiatric disease and treatment · 2015Article
- Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review.Neuropsychiatric disease and treatment · 2014Review
- Treatment of focal dystonia.Current treatment options in neurology · 2012Article
- Therapeutics in Huntington's Disease.Current treatment options in neurology · 2012Article
- Mind the gap: a German case study on the discrepancy between geographic accessibility and real-world utilization of botulinum toxin therapy.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum toxin (BTA) is a safe and effective therapeutic tool for many neurological conditions but few studies have investigated its real cost in neurological practice. We evaluated the daily cost of botulinum toxin type A (BTA) treatment through a cost effectiveness analysis alongside a prospective study of BTA injections at a French University Hospital over a 2-year follow-up period. The data of 3,108 BTA injections performed in 870 adult patients presenting with dystonia, facial hemispasm, or spasticity were entered in the database. Patients were questioned at each visit about the subjective effectiveness of the previous injection. The daily cost of BTA treatment was calculated as the ratio of each session's cost (including all additional costs) to the duration of subjective efficacy. The subjective rating of efficacy duration was 17.3 ± 7.7 weeks for facial hemispasm, 15.4 ± 7.7 for blepharospasm, 14.3 ± 6.7 for cervical dystonia, 14.5 ± 7.8 and 14.1 ± 7.4 weeks for upper and lower limb spasticity, respectively. The daily cost of BTA injections was 0.57 ± 0.20 <euro> for facial hemispasm, 0.95 ± 0.30 <euro> for blepharospasm, 2.85 ± 0.86 <euro> for cervical dystonia, 3.38 ± 1.49 <euro> and 3.62 ± 1.81 <euro> for upper and lower limb spasticity, respectively. When associated costs were considered, the daily cost of BTA injections was clearly increased (45-93%) in limb spasticity or rigidity but remained only modestly increased (15-37%) in other indications. These results obtained in a large cohort of patients show that BTA treatment has a low daily cost for a long-lasting effect, with a daily cost/benefit ratio that greatly depends on the indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.